Pam2CSK4 (TFA)

CAT:
804-HY-P1181A-01
Size:
1 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Pam2CSK4 (TFA) - image 1

Pam2CSK4 (TFA)

  • UNSPSC Description:

    Pam2CSK4 (TFA), a lipopeptide, is a TLR6-independent TLR2 ligand and agonist. Pam2CSK4 (TFA) promotes platelet aggregation, and increases platelet adhesion to collagen-coated surfaces in a TLR2/NF-κB/BTK-dependent manner. Pam2CSK4 (TFA) also activates iNOS expression and NO production in mouse macrophages[1][2][3].
  • Target Antigen:

    Toll-like Receptor (TLR)
  • Type:

    Peptides
  • Related Pathways:

    Immunology/Inflammation
  • Applications:

    COVID-19-immunoregulation
  • Field of Research:

    Inflammation/Immunology
  • Assay Protocol:

    https://www.medchemexpress.com/pam2csk4-tfa.html
  • Purity:

    99.28
  • Solubility:

    10 mM in DMSO|H2O : 100 mg/mL (ultrasonic)
  • Smiles:

    O=C(C(F)(F)F)O.O=C(N[C@@H](CCCCN)C(N[C@H](C(O)=O)CCCCN)=O)[C@H](CCCCN)NC([C@H](CCCCN)NC([C@H](CO)NC([C@@H](N)CSC[C@H](OC(CCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCC)=O)=O)=O)=O.[x]
  • Molecular Weight:

    1271.82 (free base)
  • References & Citations:

    [1]Parra-Izquierdo I, et al. The Toll-Like Receptor 2 Ligand Pam2CSK4 Activates Platelet Nuclear Factor-κB and Bruton's Tyrosine Kinase Signaling to Promote Platelet-Endothelial Cell Interactions. Front Immunol. 2021 Aug 30;12:729951.|[2]Kaur A, et al. An efficient and scalable synthesis of potent TLR2 agonistic PAM2CSK4. RSC Adv. 2018 Mar 5;8(18):9587-9596.|[3]Kulsantiwong P, et al. Pam2CSK4 and Pam3CSK4 induce iNOS expression via TBK1 and MyD88 molecules in mouse macrophage cell line RAW264.7. Inflamm Res. 2017 Oct;66(10):843-853.
  • Shipping Conditions:

    Blue Ice
  • Storage Conditions:

    -80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
  • Clinical Information:

    No Development Reported